Lipocine (NASDAQ:LPCN) Lifted to Buy at StockNews.com

Lipocine (NASDAQ:LPCN) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

Lipocine Stock Performance

Shares of LPCN stock traded up $0.02 during trading hours on Friday, hitting $4.41. 40,618 shares of the company were exchanged, compared to its average volume of 54,213. The company has a 50 day simple moving average of $6.99 and a two-hundred day simple moving average of $5.51. The firm has a market cap of $23.58 million, a P/E ratio of -2.58 and a beta of 1.12. Lipocine has a fifty-two week low of $2.31 and a fifty-two week high of $11.79.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $0.66 EPS for the quarter. The company had revenue of $7.62 million during the quarter. As a group, sell-side analysts expect that Lipocine will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.